ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1142

Distinct Pathways Of Ly6Chi Monocyte Development Identified By a Novel Dual-Reporter Murine Myeloid Progenitor Cell Line

Pui Lee1, David Sykes2, Sarah Ameri3, Demetrios Kalaitzidis2, Peter A. Nigrovic4 and Astrid Cardona5, 1Boston Children's Hospital, Boston, MA, 2Massachusetts General Hospital, Boston, MA, 3Division of Rheumatology, Immunology, and Allergy, Brigham and Women's Hospital, Boston, MA, 4Division of Immunology, Boston Children's Hospital, Boston, MA, 5University of Texas - San Antonio, San Antonio, MA

Meeting: 2013 ACR/ARHP Annual Meeting

Keywords: inflammation and monocytes

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Title: Innate Immunity and Rheumatic Disease

Session Type: Abstract Submissions (ACR)

Background/Purpose: Monocytes are essential to innate immunity but also propagate the inflammatory response in autoimmune arthritis and crystal arthropathies.  Development of inflammatory monocytes (Ly6Chi CCR2+) and residential monocytes (Ly6Clo CX3CR1+) from murine bone marrow precursor cells is an enigmatic process that involves numerous transcription factors with influence by growth factors and cytokines. Elucidation of these critical pro-inflammatory pathways is limited by the paucity of precursor cells and the need for extensive ex-vivo manipulation and cell sorting.

Methods: To develop an informative myeloid cell line, we infected bone marrow from CCR2RFP/+ CX3CR1GFP/+ dual-reporter mice with a murine stem cell virus encoding Hoxb8 under the control of estrogen receptor. These cells remain immortalized at the myeloid precursor stage until induced by estrogen withdrawal to initiate synchronous myeloid differentiation. To identify pathways important to monocyte development, small molecule inhibitors, cytokines and growth factors were added to cell culture at specific timepoints, and key findings were confirmed in live mice.

Results: Upon cessation of Hoxb8 expression after estrogen withdrawal, our novel dual-reporter cell line spontaneously differentiated into Ly6Chi CCR2+ inflammatory monocytes, followed by maturation to Ly6Clo CX3CR1+ residential monocytes.  Using this cell line as a screening tool, we identified an essential role of phosphoinositide-3 kinase (PI3K) and mechanistic target of rapamycin (mTOR) in spontaneous monocyte development through a small molecule library screen.  These findings were confirmed in vivo as mice with conditional deletion of mTOR complex 1, but not mice lacking mTOR complex 2, failed to develop Ly6Chi monocytes.  While macrophage colony-stimulating factor (M-CSF) was not required for spontaneous production of monocytes, the addition of exogenous M-CSF induced Ly6Chi monocyte development via a PI3K/mTOR-independent pathway.

Conclusion: We describe a novel dual-reporter myeloid progenitor cell line that recapitulates the monocyte development continuum. Studies using these cells enabled identification of a previously unrecognized role of mTORC1 in normal development of inflammatory monocytes, as well as a potential “rescue” pathway of mTORC1-independent differentiation.  Our work highlights the utility of this technology in studying myeloid differentiation and provides evidence for the existence of two distinct pathways of monocyte production that may be differentially employed in physiologic and inflammatory conditions.


Disclosure:

P. Lee,
None;

D. Sykes,
None;

S. Ameri,
None;

D. Kalaitzidis,
None;

P. A. Nigrovic,

Baxter Healthcare,

2,

Novartis Pharmaceutical Corporation,

5;

A. Cardona,
None.

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2013 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/distinct-pathways-of-ly6chi-monocyte-development-identified-by-a-novel-dual-reporter-murine-myeloid-progenitor-cell-line/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology